THE APEX TIMES
Johnson & Johnson says FDA has cleared AI features for MONARCH QUEST 3 bronchoscopy system
The medical device company received U.S. regulatory clearance for a software update to its robotic-assisted bronchoscopy platform, adding AI-powered tools aimed at supporting clinicians during lung procedures.
Johnson & Johnson (JNJ) said the U.S. Food and Drug Administration has cleared an AI-powered software update for its MONARCH QUEST 3 bronchoscopy system, a robotic-assisted device used to navigate airways to locate and access areas of the lung for diagnostic procedures.
MONARCH QUEST 3 is part of J&J’s Monarch platform, which combines imaging and automated guidance to help clinicians perform bronchoscopy with a more targeted approach than traditional manual methods. In this update, the company introduced new software capabilities intended to support the procedure through AI-powered tools.
According to the report, the FDA clearance covers MONARCH QUEST 3 software, rather than a new hardware system. That distinction matters because software clearances are typically tied to specific functions within a platform, with documentation focused on how the added tools perform and what changes they introduce to the device workflow.
The clearance was disclosed in a market-news write-up carried by Yahoo Finance. The item describes the update as “AI powered” and characterizes it as part of a software revision to the MONARCH QUEST 3 platform, implying J&J believes the AI tools are sufficiently validated for the intended clinical use under FDA rules.
J&J has been working to expand the footprint of its interventional pulmonology offerings as healthcare providers increasingly look for tools that can improve targeting and procedural efficiency. Devices like robotic bronchoscopy sit at the intersection of medical robotics and diagnostic imaging, where software improvements can be a recurring way to iterate capability without replacing the full device.
In the same vein, AI features in clinical devices are often positioned as decision-support or workflow-assist tools, designed to help practitioners interpret information and execute steps more consistently. Even when AI is included, the FDA approval generally reflects that the system’s performance and safety meet regulatory criteria for the specific claims and operating environment.
What the report does not detail is as important as what it states. It does not provide specifics on the exact AI functions included in the clearance, the nature of the AI outputs (for example, how the tools present guidance), the FDA decision date, or any study results or performance metrics underpinning the clearance.
Investors and clinicians will likely watch for additional company statements that clarify what the newly cleared AI tools do in practice, how they change the MONARCH QUEST 3 workflow, and when J&J expects the update to be broadly available in clinical settings.
Why It Matters
- AI features are increasingly finding their way into regulated medical devices, and FDA clearance can accelerate adoption if clinicians and hospitals view the tools as practical and reliable.
- Because the update is software-based, J&J may be able to iterate functionality on an installed base, potentially reducing friction compared with deploying wholly new hardware.
- Robotic-assisted bronchoscopy is a competitive and clinically important area of interventional pulmonology, where software improvements can influence procedure outcomes and operational efficiency.
- The next questions for the market are the scope of the AI functionality and evidence behind the clearance, which can affect both reimbursement discussions and purchasing decisions.
Sources
Key Facts
- Johnson & Johnson said the FDA cleared an AI-powered software update for the MONARCH QUEST 3 bronchoscopy system.
- MONARCH QUEST 3 is a robotic-assisted bronchoscopy platform used to navigate airways to access areas of the lung.
- The clearance described relates to a software revision to the existing system rather than a newly announced hardware model.
- The update is characterized as adding AI-powered tools intended to support clinicians during bronchoscopy procedures.
- The disclosure was reported via Yahoo Finance. Details beyond the existence of clearance and AI-powered tools were not provided in the excerpted market-news item.
Healthcare Related
Microsoft Shares Linger in Consolidation as Analysts Track an Azure AI Cost Wave
A market-focused note points to Azure momentum and a stock that remains range-bound, while at least one long-term buyer says higher spending ahead is already being priced in unevenly.
Chevron points to potential growth after an Angola oil and gas discovery, with a possible tie-back to existing infrastructure
A new discovery in Angola is being framed as an opportunity to add reserves and production capacity, potentially through development options that leverage nearby facilities. Chevron has not, in the coverage reviewed here, provided detailed field parameters or timing.
Analysts point to a broader AI hardware stack, from chips to fiber as investors weigh who wins next
A recent market roundup argues that the next wave of AI beneficiaries may extend beyond NVIDIA’s GPUs to include companies supplying the networking and optical infrastructure that moves AI data.
Bitcoin holds around $65,000 as BlackRock and Citi announcement stepped-up support for crypto custody
Markets are watching a key psychological level as BlackRock reportedly supports modest portfolio exposure to bitcoin and Citi prepares bitcoin custody services on its Custody+ platform.
Einride buys Tesla Semi trucks for North American logistics rollout, lifting and then easing shares
The Swedish autonomous-transport company said it has purchased several hundred Tesla Semi trucks that it plans to deploy for Amazon and other customers in North America, triggering a sharp market reaction in shares.
Yahoo Finance calls out Broadcom’s earnings growth as key to chasing a $3 trillion valuation tier that Microsoft has reached
A Yahoo Finance analysis on Aug. 18, 2026 argued that Broadcom’s recent earnings momentum could position the semiconductor company to catch up to the valuation scale associated with Microsoft, which the piece framed as being in the “$3 trillion club.”
Eli Lilly closes the gap with Novo as weight-loss drug race tightens, per market-watchers
Eli Lilly was named “Stock of the Day,” with market commentary arguing it is catching up after an earlier advantage for Novo Nordisk in weight-loss drug performance. The post also flagged two possible share-price entry points, reflecting a still-volatility-prone setup.
Yahoo Finance pits EMBJ against RTX in a value-stock comparison focused on market multiples
A new market note weighs whether investors should prefer RTX, the defense prime, or EMBJ based on valuation yardsticks rather than business outlook.
Meta shares slip as investors balk at the pace of AI spending, despite record ad performance and rising daily users
A market selloff is testing confidence in Meta’s push to scale artificial intelligence across its ad systems and platforms, even as user metrics and revenue momentum remain strong.
Amazon’s $10B Houston data-center campus draws scrutiny as Texas tightens rules
A planned multi-year Amazon Web Services facility near Houston, described as a roughly $10 billion investment, is facing added attention over how much detail is shared publicly and how it fits with Texas’s evolving data-center requirements.